... from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Relapse Chronic myeloid leukemia Dasatinib Imatinib Discontinuation With the advent of BCR::ABL1 tyrosine kinase inhibitors (TKIs), the outcome of patients with chronic myeloid...

.../discontinuations occurred while on imatinib (36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/discontinuations occurred due to side effects/intolerance (46/69; 67%); other reasons included a wish to conceive (6/69; 9%) and attempts to achieve treatment-free remission (TFR) (6/69; 9%). Interruptions due...

...Jiaqi Tan; Mengxing Xue; Jinlan Pan; Jiannong Cen; Xiaomei Qi; Ping Liu; Xiaohong Zhao; Pin Wu; Qinrong Wang; Dandan Liu; Yuejun Liu; Suning Chen; Zhi Wang We retrospectively evaluated the efficacy and safety of dasatinib among 48 Chinese patients with chronic phase chronic myeloid leukaemia...

...Mohamed Shanshal; Andrew Shakespeare; Seshadri Thirumala; Boyd Fenton; Donald P. Quick Dasatinib is a potent inhibitor of the altered tyrosine kinase activity in disease states associated with BCR/ABL1. This agent has been shown to exhibit broad off-target kinase inhibition and immunomodulating...

... Lorand-Metze; Katia Borgia Barbosa Pagnano Early reduction of BCR-ABL1 transcript levels has been associated with improved outcome in chronic myeloid leukemia (CML) treatment. We evaluated 54 chronic-phase CML patients treated with imatinib who switched therapy to dasatinib (n = 33) or nilotinib (n = 21...

... according to 3-month BCR-ABL levels across several clinical trials [ 31,41,42,44,45,46,47 ] In a retrospective analysis of the phase III DASISION trial, achieving BCR-ABL transcript levels of ≤10% at 3 months, compared with levels of >10%, in both the dasatinib and imatinib arms, provided...

... therapy with dasatinib, intrathecal chemotherapy and cranial irradiation. Subsequently, 168 days after allogeneic HSCT, he was started on dasatinib maintenance therapy to prevent a CNS relapse. Thirty-eight months after allogeneic HSCT, he has sustained a complete molecular response in both bone marrow...

... month of treatment. During the follow-up, his lymphocyte number doubled in <6 months. Based on previous reports, dasatinib was chosen instead of imatinib. After 6 months of treatment with 100 mg/day of dasatinib, the patient demonstrated a partial response, characterized by the regression of lymph...

... have undergone prior allo-HSCT. This report presents the case of a patient with a post-transplant persistent positive BCR/ABL value, who was treated with imatinib and dasatinib before a second allo-HSCT. The patient started taking nilotinib due to a persistent BCR/ABL value and residual mass in her...